203 related articles for article (PubMed ID: 19861338)
1. Molecular screening for rifampicin and fluoroquinolone resistance in a clinical population of Brucella melitensis.
Valdezate S; Navarro A; Medina-Pascual MJ; Carrasco G; Saéz-Nieto JA
J Antimicrob Chemother; 2010 Jan; 65(1):51-3. PubMed ID: 19861338
[TBL] [Abstract][Full Text] [Related]
2. In vitro selection of fluoroquinolone resistance in Brucella melitensis.
Ravanel N; Gestin B; Maurin M
Int J Antimicrob Agents; 2009 Jul; 34(1):76-81. PubMed ID: 19261448
[TBL] [Abstract][Full Text] [Related]
3. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
[TBL] [Abstract][Full Text] [Related]
4. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Qatar between 2014 - 2015.
Deshmukh A; Hagen F; Sharabasi OA; Abraham M; Wilson G; Doiphode S; Maslamani MA; Meis JF
BMC Microbiol; 2015 Jun; 15():121. PubMed ID: 26073177
[TBL] [Abstract][Full Text] [Related]
5. Rifampicin resistance phenotyping of Brucella melitensis by rpoB gene analysis in clinical isolates.
Sayan M; Yumuk Z; Dündar D; Bilenoglu O; Erdenlig S; Yaşar E; Willke A
J Chemother; 2008 Aug; 20(4):431-5. PubMed ID: 18676221
[TBL] [Abstract][Full Text] [Related]
6. Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism.
Beeton ML; Chalker VJ; Kotecha S; Spiller OB
J Antimicrob Chemother; 2009 Sep; 64(3):529-38. PubMed ID: 19567408
[TBL] [Abstract][Full Text] [Related]
7. Molecular epidemiological and antibiotic susceptibility characterization of Brucella isolates from humans in Sicily, Italy.
Marianelli C; Graziani C; Santangelo C; Xibilia MT; Imbriani A; Amato R; Neri D; Cuccia M; Rinnone S; Di Marco V; Ciuchini F
J Clin Microbiol; 2007 Sep; 45(9):2923-8. PubMed ID: 17634297
[TBL] [Abstract][Full Text] [Related]
8. Emergence of quinolone-resistant, topoisomerase-mutant Brucella after treatment with fluoroquinolones in a macrophage experimental infection model.
Rodríguez Tarazona E; García Rodríguez JÁ; Muñoz Bellido JL
Enferm Infecc Microbiol Clin; 2015 Apr; 33(4):248-52. PubMed ID: 24913992
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
Zhou Y; Yu L; Li J; Zhang L; Tong Y; Kan B
Int J Antimicrob Agents; 2013 Jul; 42(1):72-5. PubMed ID: 23643392
[TBL] [Abstract][Full Text] [Related]
10. The role of intra- and extragenic compensatory mutations in the suppression of fluoroquinolone resistance in a Salmonella Typhimurium gyrA mutant (D87G).
Preisler A; Heisig P
J Antimicrob Chemother; 2009 Feb; 63(2):290-4. PubMed ID: 19033246
[TBL] [Abstract][Full Text] [Related]
11. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China.
Liu ZG; Di DD; Wang M; Liu RH; Zhao HY; Piao DR; Zhao ZZ; Hao YQ; Du YN; Jiang H; Cui BY; Xia XZ
BMC Infect Dis; 2018 Jan; 18(1):43. PubMed ID: 29338693
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological and phylogenetic analysis of Spanish human Brucella melitensis strains by multiple-locus variable-number tandem-repeat typing, hypervariable octameric oligonucleotide fingerprinting, and rpoB typing.
Valdezate S; Navarro A; Villalón P; Carrasco G; Saéz-Nieto JA
J Clin Microbiol; 2010 Aug; 48(8):2734-40. PubMed ID: 20554816
[TBL] [Abstract][Full Text] [Related]
13. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
[TBL] [Abstract][Full Text] [Related]
14. Genetic diversity of Brucella abortus and Brucella melitensis in Kazakhstan using MLVA-16.
Shevtsov A; Ramanculov E; Shevtsova E; Kairzhanova A; Tarlykov P; Filipenko M; Dymova M; Abisheva G; Jailbekova A; Kamalova D; Chsherbakov A; Tulegenov S; Akhmetova A; Sytnik I; Karibaev T; Mukanov K
Infect Genet Evol; 2015 Aug; 34():173-80. PubMed ID: 26160544
[TBL] [Abstract][Full Text] [Related]
15. In vitro-selected resistance to fluoroquinolones in two Brucella strains associated with mutational changes in gyrA.
Turkmani A; Psaroulaki A; Christidou A; Chochlakis D; Tabaa D; Tselentis Y
Int J Antimicrob Agents; 2008 Sep; 32(3):227-32. PubMed ID: 18583100
[TBL] [Abstract][Full Text] [Related]
16. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of strains of fluoroquinolone-resistant Salmonella enterica serovar Schwarzengrund carrying multidrug resistance isolated from imported foods.
Akiyama T; Khan AA
J Antimicrob Chemother; 2012 Jan; 67(1):101-10. PubMed ID: 22010209
[TBL] [Abstract][Full Text] [Related]
18. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.
Balsalobre L; de la Campa AG
Antimicrob Agents Chemother; 2008 Mar; 52(3):822-30. PubMed ID: 18160515
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey.
Denk A; Demirdag K; Kalkan A; Ozden M; Cetinkaya B; Kilic SS
Infect Dis (Lond); 2015 Jun; 47(6):364-9. PubMed ID: 25712728
[TBL] [Abstract][Full Text] [Related]
20. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
